文献速递复苏、休克与脓毒症心脑血管急症重症综合管理与镇静镇痛

Impella与体外膜氧合在心源性休克中的比较:系统评价与Meta分析

IMPELLA VERSUS EXTRACORPOREAL MEMBRANE OXYGENATION IN CARDIOGENIC SHOCK: A SYSTEMATIC REVIEW AND META-ANALYSIS.
PubMed 文献 · Shock · 2022-10-04
一句话结论心源性休克患者中,Impella较ECMO与更低的院内全因死亡、出血和卒中风险相关,但30天和12个月死亡率无显著差异。

该系统评价与Meta分析检索截至2022年5月10日的多个数据库,纳入10项比较Impella与ECMO在心源性休克中结局的研究,共1,827例接受机械循环支持的患者。结果显示Impella组院内全因死亡风险显著低于ECMO组(RR 0.80,95%CI 0.65-1.00,P=0.05),30天(RR 0.97,95%CI 0.82-1.16,P=0.77)和12个月(RR 0.90,95%CI 0.74-1.11,P=0.32)死亡率无显著差异。成功脱离MCS(RR 0.97,95%CI 0.81-1.15,P=0.70)和桥接至移植(RR 0.88,95%CI 0.58-1.35,P=0.56)无显著差异。Impella组出血和卒中风险低于ECMO组。作者认为需要未来足够样本量的随机研究证实。

要点

  • Impella组院内全因死亡风险较ECMO组显著降低(RR 0.80,95%CI 0.65-1.00,P=0.05)。
  • 30天(RR 0.97,95%CI 0.82-1.16,P=0.77)和12个月(RR 0.90,95%CI 0.74-1.11,P=0.32)死亡率两组无显著差异。
  • 成功脱离MCS(RR 0.97,95%CI 0.81-1.15,P=0.70)和桥接至移植(RR 0.88,95%CI 0.58-1.35,P=0.56)无显著差异。
  • Impella组出血和卒中风险低于ECMO组。
  • 作者认为需要未来足够样本量的随机研究证实这些发现。

适用人群与场景

  • 心源性休克(CS)患者
  • 比较Impella与ECMO的临床结局

研究设计与关键结果

  • 系统评价与Meta分析,纳入10项研究,共1,827例接受机械循环支持(MCS)的CS患者。
  • 院内全因死亡:Impella组风险显著低于ECMO组(RR 0.80,95%CI 0.65-1.00,P=0.05)。
  • 30天全因死亡:两组无统计学显著差异(RR 0.97,95%CI 0.82-1.16,P=0.77)。
  • 12个月全因死亡:两组无统计学显著差异(RR 0.90,95%CI 0.74-1.11,P=0.32)。
  • 成功脱离MCS:两组无显著差异(RR 0.97,95%CI 0.81-1.15,P=0.70)。
  • 桥接至移植:两组无显著差异(RR 0.88,95%CI 0.58-1.35,P=0.56)。
  • Impella组出血和卒中风险低于ECMO组。

证据类型、等级与局限

  • 证据类型:系统评价与Meta分析(随机效应模型计算风险比RR及95%CI)。
  • 局限:作者指出需要未来足够样本量的随机研究证实这些发现。

对床旁实践的改变

  • 原文未据此给出推荐;作者结论为Impella与较低的院内死亡、出血和卒中风险相关,需未来足够样本量的随机研究证实。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Background: Cardiogenic shock (CS) carries high mortality. The roles of specific mechanical circulatory support (MCS) systems are unclear. We compared the clinical outcomes of Impella versus extracorporal membrane oxygenation (ECMO) in patients with CS. Methods: This is a systematic review and meta-analysis that was conducted in accordance with Preferred Reporting Items for Systematic Reviews and Meta Analyses guidelines. We searched PubMed, Cochrane Central Register, Embase, Web of Science, Google Scholar, and ClinicalTrials.gov (inception through May 10, 2022) for studies comparing the outcomes of Impella versus ECMO in CS. We used random-effects models to calculate risk ratios (RRs) with 95% confidence interval (CIs). End points included in-hospital, 30-day, and 12-month all-cause mortality, successful weaning from MCS, bridge to transplant, all reported bleeding, stroke, and acute kidney injury. Results: A total of 10 studies consisting of 1,827 CS patients treated with MCS were included in the analysis. The risk of in-hospital all-cause mortality was significantly lower with Impella compared with ECMO (RR, 0.80; 95% CI, 0.65-1.00; P = 0.05), whereas there was no statistically significant difference in 30-day (RR, 0.97, 95% CI, 0.82-1.16; P = 0.77) and 12-month mortality (RR, 0.90; 95% CI, 0.74-1.11; P = 0.32). There were no significant differences between the two groups in terms of successful weaning (RR, 0.97; 95% CI, 0.81-1.15; P = 0.70) and bridging to transplant (RR, 0.88; 95% CI, 0.58-1.35; P = 0.56). There was less risk of bleeding and stroke in the Impella group compared with the ECMO group. Conclusions: In patients with CS, the use of Impella is associated with lower rates of in-hospital mortality, bleeding, and stroke than ECMO. Future randomized studies with adequate sample sizes are needed to confirm these findings.

来源:Shock,查看原文。版权归原作者所有。

参考来源

  1. Abusnina W, Ismayl M, Al-Abdouh A, et al. IMPELLA VERSUS EXTRACORPOREAL MEMBRANE OXYGENATION IN CARDIOGENIC SHOCK: A SYSTEMATIC REVIEW AND META-ANALYSIS. Shock. 2022. PMID: 36445229. doi:10.1097/SHK.0000000000001996

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。